Here’s what you should know:
1. The office approved Immuron’s “Anti-LPS Enriched Immunoglobulin for Use in treatment and/or Prophylaxis of a Pathological Disorder” patent.
2. The patent is comprised of 10 allowed claims. It covers Immuron’s method for treating NASH with a colostrum-based composition.
3. Bristol-Myers Squibb and Pfizer each recently increased efforts to “bolster product development in the sector,” according to Immuron’s release.
Immuron’s Interim CEO Jerry Kanellos said, “This new patent is a key milestone for Immuron as it further establishes the intellectual property position of our NASH program in the U.S. and complements the patents already granted in Australia. We believe this success paves the way for patent grants in other key jurisdictions, strengthening Immuron’s presence in the global NASH treatment market.”
More articles on gastroenterology:
Common deficiencies AAAASF cites & how to fix them — continuing discussion on keeping up with documentation
‘Data is the crux of outpatient TJR’ — 2 physicians share strategies to build strong data platforms in ASCs
15 ASCs & outpatient facilities achieving accreditation — October 2017
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.